This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Trauma patients administered oral THC consume fewer opioids than do similarly matched controls, according to clinicaltrial data published in the journal Trauma Surgery & Acute Care. Additional information on the relationship between cannabis and opioids is available in the NORML fact-sheet here.
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. . This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada. ABOUT SANTÉ CANNABIS.
As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. References Staff, T.
Now, patients affected by TRD – who didn’t respond to at least two other antidepressants – no longer need to use an antidepressant in order to benefit from ketamine-based therapy. If you are curious about ketamine therapy for depression, you may still have questions, such as: How is ketamine different from other antidepressants?
We look forward to his expertise as we expand our mental health analytical platform and enter clinicaltrials. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Ehave, Inc.
IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinicaltrial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.
INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.
While PTSD can be treated with therapies and pharmaceutical medications, those are not always successful and additional treatments are necessary. When the body is defensive against trauma, this system begins to fail, resulting in physical, mental and/or neurological conditions. Get your Florida Medical Marijuana Card.
A new review published by scientific journal, Pharmacology Biochemistry and Behavior , has found that marijuana cannabinoid, CBD, is a “promising” therapy for treating cocaine dependence. Exploring alternative therapies, researchers turned their attention to marijuana cannabinoid, cannabidiol – more commonly referred to as CBD.
As the medical community delves into the therapeutic potential of cannabis, certain health conditions have emerged as primary candidates for its prescription. THC, the psychoactive component of cannabis, has analgesic properties that can help manage chronic pain conditions, such as neuropathic pain and arthritis.
In the largest clinicaltrial to date, a new study conducted by the UK-based pharmaceutical company Compass Pathways shows that psilocybin or “magic” mushrooms can safely relieve depression. The trial included 233 patients from 10 countries in North America and Europe. Food and Drug Administration. Rate this blog post.
In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine. Cannabinoid Therapies for Cancer Patients. Today there are 41 states that have enacted some form of a Right to Try or RTT laws. A Push by Patients.
Instead, patients turn to a mix of whatever individual medications, therapies, and lifestyle changes (especially exercise) help ease symptoms and improve quality of life. They report that oral feeding of a single dose of cannabis oil was enough to mitigate some hallmarks of the condition in mice. It’s not a new idea.
Notably, the grant program will target three prevalent and often debilitating conditions in military personnel: PTSD, traumatic brain injury (TBI) , and chronic traumatic encephalopathy (CTE). This could foster a pool of experts well-versed in applying psychedelic-assisted therapy.
The study concludes by stating that “To our knowledge, this is the first randomized controlled trial to demonstrate the benefit of cannabis oil – a THC-rich whole plant extract – on symptoms and on [the] quality of life of people with fibromyalgia. Interested in reading the study’s full abstract? mg/mL of THC and 0.51
House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinicaltrials involving cannabis. Senator Anna Wishart (D) has re-introduced legislation, LB 110, to allow qualifying patients with certain debilitating conditions to use and safely access medical cannabis.
This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinicaltrials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5 th , 2022 to include access to psychedelic compounds on a case-by-case basis.
COMPASS used their own psilocybin, called COMP360, to lead the largest randomized, controlled, double-blind study into psilocybin therapy, the results of which were shared at the American Psychiatric Association’s (APA) annual meeting in New Orleans. Food and Drug Administration (FDA) for the treatment of TRD.
Post-Traumatic Stress Disorder (PTSD) is a multifaceted mental health condition triggered by experiencing or witnessing traumatic events, persistently manifesting in symptoms like flashbacks, severe anxiety, and disrupted sleep. Looking ahead, the future of medical cannabis in PTSD treatment hinges on overcoming these challenges.
Canada recently amended its Controlled Drugs and Substances Act (CDSA) to allow for psilocybin and MDMA therapy in limited circumstances. Subsection 56(1) of the CDSA will exempt medical providers from enforcement of the CDSA when providing psilocybin and MDMA treatment to patients suffering serious or terminal health conditions.
MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need.
As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinical research is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. References Staff, T.
Alternative medicine is becoming more widely acknowledged and practiced than ever before, opening the door for therapies like psychedelics to enter the world of mainstream healthcare. Psilocybin therapy is both studied and used by highly legitimate medical establishments. Ned Lamont signed a bill (HB 5506) to fund psychedelic therapy.
In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. However, it is also being used for off-label infusions for the management of psychiatric disorders and chronic pain management (enter the clinics).
New therapy exploration suggest potential in using psilocybin for OCD symptoms. And it further reinforces the need to carry out clinicaltrials to determine the safety and efficiency of using psilocybin to treat OCD. Preliminary findings have suggested that mental health patients could go through psilocybin-assisted therapy.
Living with chronic conditions such as Multiple Sclerosis (MS) is profoundly challenging and impacts various aspects of daily life. Disease-modifying therapies (DMTs) are essential in altering the immune response to reduce inflammation and prevent further damage to the nervous system.
Advanced Illness , Oregon Psilocybin Advisory Board , Oregon Psilocybin Services Act , Psilocybin , Psilocybin Therapy , Psychedelics , Right To Try. A multitude of recent clinicaltrials shows the clear promise of psilocybin for this population suffering from these debilitating conditions.
The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinicaltrial for depression is making excellent progress. His background is a mix of cognitive psychology, clinical psychology and computer science. Diversified Drug Development.
It can be caused by a variety of factors, including medical conditions, psychological issues, or environmental factors. It can be caused by underlying health conditions, medications, or psychological factors. Comorbid Insomnia : Also known as secondary insomnia, it occurs alongside another medical or psychiatric condition.
The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. BUFFALO, N.Y. , Aug. Tweet this.
After a psilocybin treatment,(it’s like) you’re still in your car, in traffic, but you have the windows up; the air conditioning is on and it’s quiet. Before January, people could only access psychedelic-assisted psychotherapy through clinicaltrials or medical exemptions. It’s just you and the music.”
Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinicaltrials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinicaltrials to further advance these promising therapies.
Of those states that had legalized medical marijuana, 14 currently consider Parkinson’s disease a qualifying condition for medical marijuana therapies. Responses came from 49 states, of which 15 had not currently legalized medical marijuana at the time of the study. Florida is among these states.
Of these consumers, over half said the drug had a beneficial clinical effect on their condition. As medicinal cannabis treatments are now legal in many parts of the world, naturally, there is a growing interest in whether the products can treat neurological conditions like Parkinson’s disease. Parkinson’s disease and cannabis.
#image_title Families affected by Huntington’s Disease (HD) know to well that this hereditary neurodegenerative condition progressively impacts movement, cognition, and behavior, profoundly affecting both patients and their loved ones. “Every patient I see brings more than just their symptoms.”
(TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce that following discussions with the U.K. Small Pharma initiated a clinical program into DMT-assisted therapy in February 2021. About Small Pharma. Small Pharma Inc.
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a ClinicalTrial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinicaltrial for INM-755 in healthy volunteers. VANCOUVER, Nov.
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a ClinicalTrial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinicaltrial for INM-755 in healthy volunteers. VANCOUVER, Nov.
Healthcare Ketamine therapy has delivered positive results for patients when used in a structured outpatient setting. In Manhattan alone, 12 clinics have already opened their doors. Many clinics are capitalizing on an opportunity to use ketamine therapy as a treatment for alcoholism, among many other things.
These findings could point to new cannabis-based therapies for both the healing of broken bones and the slowing of degenerative osteoporosis. Multiple experimental and clinicaltrials have portrayed CBD as a safe agent, suggesting further studies in humans to assess its usefulness for improving fracture healing.
MYMD-1 is also being developed as a potential therapy for COVID-19-related conditions such as post-COVID-19 syndromes. Supera-CBD is being developed to address anxiety, chronic pain, addiction, and seizures, and is on a path toward human clinicaltrials as a therapy for epilepsy, followed by chronic pain.
INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinicaltrial for IGC-AD1. The results of the clinicaltrial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.
Whether you’re dealing with a sports injury or chronic pain conditions, CBD might offer some relief. CBD has been found to have anti-inflammatory effects , which can help with conditions like arthritis, muscle soreness, and even more serious inflammatory diseases. Now, how does CBD compare with traditional pain medications ?
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content